A novel prognostic scoring system for NLPHL
1UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER.
In this issue of Blood, Hartmann and colleagues from the German Hodgkin Study Group (GHSG) conducted a review of pathologic features and clinical data from 423 patients with nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL) treated across 9 of their prospective clinical trials. First, they determined that patients with histologic variants have a higher chance of having advanced-stage disease and a greater risk for disease progression or relapse at 5 years. Second, they were able to establish a prognostic scoring model that defines 3 discrete risk groups based on the factors of variant histopathologic growth pattern, low serum albumin, and male gender.
In this issue of Blood, Hartmann and colleagues from the German Hodgkin Study Group (GHSG) conducted a review of pathologic features and clinical data from 423 patients with nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL) treated across 9 of their prospective clinical trials. First, they determined that patients with histologic variants have a higher chance of having advanced-stage disease and a greater risk for disease progression or relapse at 5 years. Second, they were able to establish a prognostic scoring model that defines 3 discrete risk groups based on the factors of variant histopathologic growth pattern, low serum albumin, and male gender.
